the completed phase ii trial, dubbed renew by biogen, studied the potential clinical efficacy of opicinumab in treating aon, more specifically in repairing damage done to the optic nerve. the study successfully reached its primary endpoint and showed a 34 percent partial recovery of optic nerve latency, a measure of the time of conduction from the retina to the visual cortex. on renew's secondary endpoint, there was no statistically significant change in either visual function or retinal thickness.